ArticleNature chemical biology2026
Engineering synthetic agonists for targeted activation of Notch signaling.
Article in Nature chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and preclinical evaluation of a decoy DLL4-encoding oncolytic HSV-1 for high-grade glioma.Oncogene · 2026Article
- Notch signaling in the tumor microenvironment: recent advances and targeted therapeutics.Molecular cancer · 2026Review
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
Notch signaling regulates cell fate decisions and has context-dependent tumorigenic or tumor suppressor functions. Although there are several classes of Notch inhibitors, the mechanical force requirement for Notch activation has hindered attempts to generate soluble agonists. To address this problem, we engineered synthetic Notch agonists (SNAGs) by tethering affinity-matured Notch ligands to proteins that internalize their targets. This bispecific format enables SNAGs to 'pull' on mechanosensitive Notch receptors, triggering their activation in the presence of desired biomarkers. We successfully developed SNAGs targeting six independent surface markers, including the tumor antigens PDL1, CD19 and HER2 and the immunostimulatory receptor CD40. HER2-SNAGs and CD19-SNAGs increased the expression of T cell activation markers and Notch target genes in cocultures with tumor cells, highlighting their potential for immunotherapeutic applications. These insights have broad implications for the pharmacological activation of mechanoreceptors and will expand our ability to modulate Notch signaling in biotechnology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.